{"protocolSection":{"identificationModule":{"nctId":"NCT05970367","orgStudyIdInfo":{"id":"S67164"},"organization":{"fullName":"KU Leuven","class":"OTHER"},"briefTitle":"Intensive Motor Rehabilitation With Technology for Patients With Central Neurological Disease","officialTitle":"Impact of an Intensive Motor Rehabilitation Programme Integrating Technology for Adults With Central Neurological Disease: A Randomised Controlled Rehabilitation Study in the Chronic Phase","acronym":"INTeRAcT"},"statusModule":{"statusVerifiedDate":"2023-07","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-07-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-06-23","studyFirstSubmitQcDate":"2023-07-24","studyFirstPostDateStruct":{"date":"2023-08-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-07-24","lastUpdatePostDateStruct":{"date":"2023-08-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Prof Geert Verheyden","investigatorTitle":"Prof.","investigatorAffiliation":"KU Leuven"},"leadSponsor":{"name":"KU Leuven","class":"OTHER"},"collaborators":[{"name":"AZ Herentals","class":"UNKNOWN"},{"name":"Vrije Universiteit Brussel","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This project will consist of 1 large clinical trial with 2 core concepts: (1) Clinical benefits of an intensive rehabilitation programme using advanced technology, compared to the control group; (2) A full health economic evaluation combined with model-based estimation of costs and benefits."},"conditionsModule":{"conditions":["Stroke","Spinal Cord Injuries","Chronic Disease"],"keywords":["rehabilitation","intensive","technology"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Randomised controlled trial (RCT)","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intensive rehabilitation program","type":"EXPERIMENTAL","description":"3 weeks of intensive rehabilitation --\\> follow-up 9 months standard care","interventionNames":["Other: Intensive rehabilitation programme"]},{"label":"Standard care","type":"NO_INTERVENTION","description":"Follow-up 9 months standard care --\\> 3 weeks of intensive rehabilitation"}],"interventions":[{"type":"OTHER","name":"Intensive rehabilitation programme","description":"Intensive rehabilitation using advanced technology, based on the patient's goals.\n\nIncluding cardiovascular fitness training, goal-oriented training, physiotherapy with and without advanced technology and self-management.","armGroupLabels":["Intensive rehabilitation program"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Functional Independence Measure (FIM)","description":"The Functional Independence Measure (FIM), which measures independence in daily functioning after stroke. The FIM consists of 18 items designed to assess to what extent a person needs assistance in performing activities of daily living safely and efficiently. The activities consist of a number of basic skills related to self-care, pelvic floor function, transfers, gait, communication and social abilities. The FIM has acceptable reliability and has been found valid in people with stroke.\n\nMin: 13; Max: 91; Higher = better","timeFrame":"Baseline - 3weeks - 9months"},{"measure":"Change in Spinal Cord Independence Measure (SCIM)","description":"Spinal Cord Independence Measure (SCIM), an assessment of achievements of daily function of patients with spinal cord lesions. The scale consists of 19 tasks organized in 3 subscales: self-care, respiration and sphincter management, and mobility. The SCIM is valid and reliable.\n\nMin: 0; Max: 100; Higher = better","timeFrame":"Baseline - 3weeks - 9months"}],"secondaryOutcomes":[{"measure":"Change in The Canadian Occupational Performance Measure (COPM)","description":"The Canadian Occupational Performance Measure (COPM), is an evidence-based outcome measure designed to capture a patient's self-perception of performance in everyday living, over time. This outcome can be used in both study populations.\n\nMin: 1; Max: 10; Higher = better","timeFrame":"Baseline - 3weeks - 9months"},{"measure":"Change in EQ-5D-5L","description":"EQ-5D-5L, measures quality of life at five levels of health (mobility, self-care, daily activities, pain/discomfort and anxiety/depression). From this, a weighted health index can be calculated for an individual or population. This scale can also be used for both populations.\n\nMin: 1; Max: 100; Higher = better","timeFrame":"Baseline - 3weeks - every month during follow-up - 9 months"},{"measure":"Change in Goal Attainment Scaling (GAS)","description":"Goal Attainment Scaling (GAS), is an individualised evaluation method. It is scored on an ordinal 5-point scale, which captures a person's individual treatment goal and is scored afterwards on the achievement of that treatment goal. The GAS can and will be used for both stroke and spinal cord injury.\n\nMin: -2; Max: +2; Higher = better","timeFrame":"Baseline - 3weeks - 9months"},{"measure":"Change in The fatigue severity scale (FSS)","description":"The fatigue severity scale (FSS) contains 9 questions assessing the perceived severity of fatigue symptoms in the past week in various daily situations. The patient indicates the extent to which fatigue determines functioning. Again, this will be used for both stroke and spinal cord injury.\n\nMin: 9; Max: 63; Higher = worse","timeFrame":"Baseline - 3weeks - 9months"},{"measure":"Borg Rating of Perceived Exertion Scale","description":"During the intervention the Borg Rating of Perceived Exertion Scale will be completed to after every therapy block to assess subjective experiences of the patients during physical load.\n\nMin: 6; Max: 20; Higher = worse","timeFrame":"During intervention (up to 9 months)"},{"measure":"Change in the 6-minute Walk-Test (6MWT)","description":"The 6-minute Walk-Test (6MWT) is used to measure functional capacity. The maximum distance the patient can cover within 6 minutes is measured.","timeFrame":"Baseline - 3weeks - 9months (stroke only)"},{"measure":"Change in the action research Arm Test (ARAT)","description":"The action research Arm Test (ARAT) is an observational measure to assess upper extremity performance (coordination, dexterity and functioning), including 19 items. Task performance is rated on a 4-point scale, ranging from 0 (no movement) to 3 (movement performed normally).\n\nMin: 0; Max: 57; Higher = better","timeFrame":"Baseline - 3weeks - 9months (stroke only)"},{"measure":"Change in rhe Fugl-Meyer Assessment (FMA)","description":"The Fugl-Meyer Assessment (FMA) is designed to assess motor functioning in upper and lower limbs, in patients with post-stroke. Patients are assessed on 50 test items and on an ordinal 3-point scale.\n\nMin: 0; Max: 100; Higher = better","timeFrame":"Baseline - 3weeks - 9months (stroke only)"},{"measure":"Change in the functional Ambulation Classification (FAC)","description":"The functional Ambulation Classification (FAC): is a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient needs when walking, whether or not they use a personal assistive device.\n\nMin: 0; Max: 5; Higher = better","timeFrame":"Baseline - 3weeks - 9months (stroke only)"},{"measure":"Change in the 10 Meter Walk Test (10MWT)","description":"The 10 Meter Walk Test (10MWT) measures the time needed for a person to walk 10 meters. It is used to determine functional mobility and gait.","timeFrame":"Baseline - 3weeks - 9months (stroke only)"},{"measure":"Change in the Stroke Self-efficacy Questionnaire","description":"The Stroke Self-efficacy Questionnaire Evaluate individuals' confidence in carrying out activities of daily living.\n\nMin: 0; Max: 60; Higher = better","timeFrame":"Baseline - 3weeks - 9months (stroke only)"}],"otherOutcomes":[{"measure":"Change in health economic evaluation","description":"Through this questionnaire, health economic data are surveyed to estimate direct and indirect costs that participants have due to their condition.\n\nThe following types of resource use will be collected: primary care, emergency visits, inpatient stays, outpatient services, medication, transport costs, the estimation of the amount of informal care, days away from work, and social benefits (e.g. sickness leave payments).","timeFrame":"Baseline - 3weeks - every month during follow-up - 9 months"},{"measure":"Therapy diary","description":"Using a therapy diary that the investigators ask patients to fill in every time they have been to the physical therapist/psychologist. On a monthly basis, these records are requested via mail.","timeFrame":"every month during follow-up (up to 9 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures;\n2. A diagnosis of central neurological disease, made by a specialist. Conditions may include stroke or spinal cord injury:\n\n   1. Stroke: Participants must have received a diagnosis of stroke for the first time, have been diagnosed at least 3 months ago, and live at home.\n   2. SCI: Participants have a rating A, B, C or D on the American Spinal Injury Association (ASIA) measurement scale, which refers to patients with complete or incomplete impairment. All levels of SCI can be included, if there is a clear patient need linked to the upper and/or lower extremities.\n3. At least 3 months post discharge from hospital/rehabilitation centre, living at home;\n4. Having a maximum recovery of 85% of independence in daily functioning (FIM/SCIM);\n5. Had a normal functional state prior to the pathology: a pre-pathology Barthel Index \\> 85/100;\n6. Unilateral or bilateral weakness of the affected upper or lower limbs (No maximum score in all affected limbs = motricity index: score 5 on 3/3 segments)\n7. Having the clinical opportunity to engage in exercise therapy with available technology, assessed by a specialist;\n8. Age of \\> 18 years;\n9. Sufficient cognitive ability to understand the games and give informed consent, assessed by a specialist;.\n\nExclusion Criteria:\n\n1. Having other neurological or musculoskeletal conditions that may affect the protocol, assessed by a specialist;\n2. No ability to initiate movements against gravity in the upper and lower limbs;\n3. Severe visual impairment, communication, cognitive and language formation problems that would prevent the intervention and measurement process, assessed by a specialist;\n4. Any disorder, which in the investigator's opinion might the compromise participant's safety or compliance with the CIP;\n5. Female who is pregnant, breast-feeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"AZ Herentals","status":"RECRUITING","city":"Herentals","zip":"2200","country":"Belgium","contacts":[{"name":"Ingue Allewijn","role":"CONTACT","phone":"014 24 61 60","email":"ingue.allewijn@azherentals.be"}],"geoPoint":{"lat":51.17655,"lon":4.83248}},{"facility":"KU Leuven","status":"RECRUITING","city":"Leuven","zip":"3000","country":"Belgium","contacts":[{"name":"Marjan Coremans","role":"CONTACT","phone":"+32 16 19 34 52","email":"marjan.coremans@kuleuven.be"},{"name":"Geert Verheyden","role":"CONTACT","email":"geert.verheyden@kuleuven.be"},{"name":"Marjan Coremans","role":"SUB_INVESTIGATOR"},{"name":"Geert Verheyden","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":50.87959,"lon":4.70093}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000013119","term":"Spinal Cord Injuries"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000002908","term":"Chronic Disease"}],"ancestors":[{"id":"D000013118","term":"Spinal Cord Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000020196","term":"Trauma, Nervous System"},{"id":"D000014947","term":"Wounds and Injuries"},{"id":"D000020969","term":"Disease Attributes"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M15606","name":"Spinal Cord Injuries","asFound":"Spinal Cord Injury","relevance":"HIGH"},{"id":"M5837","name":"Chronic Disease","asFound":"Chronic Disease","relevance":"HIGH"},{"id":"M15605","name":"Spinal Cord Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17375","name":"Wounds and Injuries","relevance":"LOW"},{"id":"M21713","name":"Trauma, Nervous System","relevance":"LOW"},{"id":"M22390","name":"Disease Attributes","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC26","name":"Wounds and Injuries"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}